Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

Completed · Not applicable · Has a placebo group

Conditions studied: Nasal Allergy

In brief

The purpose of this study is to see if the recruitment of a certain cell type (the alpha 4 integrin (CD49d) expressing neutrophil) during a nasal allergen challenge can be inhibited by pretreatment with an FDA approved leukotriene antagonist (montelukast).

Key facts

Study ID
NCT03039101
Run by
Mitchell Grayson
People needed
25
Starts
2017-09-06
Expected to finish
2018-07-16
Last updated by the study team
2019-10-07

Who can join

Age: 21 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.